Keywords
Regenerative medicines
Personalized Therapeutics
Precision Therapy
Induced Pluripotent Stem Cells (iPSCs)
Organoids
Organ-on-Chip
Tissue Engineering
Precision Medicine
Biomaterials
3D Bioprinting
Cell Therapy
Extracellular Vesicles.
Article Number
003Abstract
Stem cells in regenerative medicine have become key players, strong potential for tissue or organ repair, replace and regenerate, disease modelling, and new therapeutics approach. Ability to self-renew and differentiate into multiple desired cell lineages ,making it more valuable for treating wide range of diseases including cardiovascular diseases, osteoarthritis disorder, neurodegenerative disorders and also in cancer. Recent research and innovation progress in pluripotent stem cells technologies, special induced pluripotent stem cells (iPSCs). have enabled therapeutics in new era of medicines. Inclusion of stem cell research with personalized medicine is supporting development of precise targeted and effective treatments with lesser side effects. Advanced technique and innovation like organoids, 3D bioprinting, disease model and organ-on-chip systems, along with biomaterial enhancement, scaffold and extracellular vesicles, improving application of the stem cells in both research and innovation as well as clinical application. Technologies provide more realistic human tissue models and improve prediction of treatment outcomes via disease models which one directly supports clinical trials. Rather than these advancements, lots of challenges remain, including standard compliance and regulatory limitations. Critical examination of translational barriers and future directions necessary to realise full clinical potential of stem cell technologies, in regenerative medicine and personalized therapeutics. Very essential to continue this interdisciplinary research and innovation with advancing safety, effectiveness and patient-specific regenerative therapies.References
Yamanaka S. Pluripotent stem cell-based cell therapy—promise and challenges. Cell Stem Cell. 2020 Oct 1;27(4):523–531. doi:10.1016/j.stem.2020.09.014.
Paliwal Swati, Chaudhuri Rituparna, Agrawal Anurag, Mohanty Sujata. Regenerative abilities of mesenchymal stem cells through mitochondrial transfer. Journal of Biomedical Science. 2018;25:31. doi:https://doi.org/10.1186/s12929-018-0429-1 .
Makarevich PI, Tkachuk VA. Fundamental and practical perspectives in regenerative medicine. Int J Mol Sci. 2024 Oct 26;25(21):11508. PMID: 39519061; PMCID: PMC11546304. doi: 10.3390/ijms252111508.
de Sá Silva F, Almeida PN, Rettore JVP, Maranduba CP, de Souza CM, de Souza GT, et al. Toward personalized cell therapies by using stem cells: seven relevant topics for safety and success in stem cell therapy. Scientifica (Cairo). 2012 Nov 20;2012:758102. PMID: 23226945; PMCID: PMC3514047. doi:10.1155/2012/758102.
Lightner AL, Chan T. Precision regenerative medicine. Stem Cell Res Ther. 2021;12:39. PMID: 33413590; PMCID: PMC7791634. doi: 10.1186/s13287-020-02092-w.
Ye L, Swingen C, Zhang J. Induced pluripotent stem cells and their potential for basic and clinical sciences. Curr Cardiol Rev. 2013;9(1):63–72. doi: 10.2174/157340313805076278.
Yang S, Hu H, Kung H, Zou R, Dai Y, Hu Y, et al. Organoids: the current status and biomedical applications. MedComm (2020). 2023;4(3):e274. PMID: 37215622; PMCID: PMC10192887. doi: 10.1002/mco2.274.
Singh D, Mathur A, Arora S, Roy S, Mahindroo N. Journey of organ on a chip technology and its role in future healthcare scenario. Adv Pharmacol Sci Adv. 2022 Apr 11;9:100246. PMCID: PMC9000345. doi:10.1016/j.apsadv.2022.100246.
Brown PT, Handorf AM, Jeon WB, Li WJ. Stem cell-based tissue engineering approaches for musculoskeletal regeneration. Curr Pharm Des. 2013;19(19):3429–3445. doi: 10.2174/13816128113199990350.
Naithani N, Sinha S, Misra P, Vasudevan B, Sahu R. Precision medicine: concept and tools. Med J Armed Forces India. 2021;77(Suppl 2):S303–S308. PMID: 34305276; PMCID: PMC8282508. doi: 10.1016/j.mjafi.2021.06.021.
Nugud A, Alghfeli L, Elmasry M, El-Serafi I, El-Serafi AT. Biomaterials as a vital frontier for stem cell-based tissue regeneration. Front Cell Dev Biol. 2022;10:713934. doi: 10.3389/fcell.2022.713934.
Tripathi S, Mandal SS, Bauri S, Maiti P. 3D bioprinting and its innovative approach for biomedical applications. MedComm (2020). 2022;3(4):e194. PMID: 36582305; PMCID: PMC9790048. doi: 10.1002/mco2.194.
El-Kadiry AEH, Rafei M, Shammaa R. Cell therapy: types, regulation, and clinical benefits. Front Med (Lausanne). 2021;8:756029. PMID: 34881261; PMCID: PMC8645794. doi: 10.3389/fmed.2021.756029.
Rafieezadeh D, Rafieezadeh A. Extracellular vesicles and their therapeutic applications: a review article (part 1). Int J Physiol Pathophysiol Pharmacol. 2024;16(1):1–9 doi:10.62347/QPAG5693.
Hoang DM, Pham PT, Bach TQ, Ngo ATL, Nguyen QT, Phan TTK, et al. Stem cell-based therapy for human diseases. Signal Transduct Target Ther. 2022;7(1):272. doi:10.1038/s41392-022-01134-4
Jain I, Chan AHP, Yang G, He H, Lam J, Sung K, et al. Combinatorial extracellular matrix tissue chips for optimizing mesenchymal stromal cell microenvironment and manufacturing. npj Regen Med. 2025;10:21. doi:10.1038/s41536-025-00408-z
Goetz LH, Schork NJ. Personalized medicine: Motivation, challenges and progress. Fertil Steril. 2018 Jun;109(6):952–963. doi: 10.1016/j.fertnstert.2018.05.006.
Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, et al. Embryonic stem cell lines derived from human blastocysts. Science. 1998;282(5391):1145–1147. doi:10.1126/science.282.5391.1145
Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861–872. doi:10.1016/j.cell.2007.11.019
Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318(5858):1917–1920. doi:10.1126/science.1151526
Daley GQ. The promise and perils of stem cell therapeutics. Cell Stem Cell. 2012;10(6):740–749. doi:10.1016/j.stem.2012.05.010
Trounson A, McDonald C. Stem cell therapies in clinical trials: progress and challenges. Cell Stem Cell. 2015;17(1):11–22. doi:10.1016/j.stem.2015.06.007
Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793–795. doi:10.1056/NEJMp1500523
Shi Y, Inoue H, Wu JC, Yamanaka S. Induced pluripotent stem cell technology: a decade of progress. Nat Rev Drug Discov. 2017;16(2):115–130. doi:10.1038/nrd.2016.245
Stadtfeld M, Nagaya M, Utikal J, Weir G, Hochedlinger K. Induced pluripotent stem cells generated without viral integration. Science. 2008;322(5903):945–949. doi:10.1126/science.1162494
Trounson A, DeWitt ND. Pluripotent stem cells progressing to the clinic. Nat Rev Mol Cell Biol. 2016;17(3):194–200. doi:10.1038/nrm.2016.10
Clevers H. Modeling development and disease with organoids. Cell. 2016;165(7):1586–1597. doi:10.1016/j.cell.2016.05.082
Rowley JA, Madlambayan G, Mooney DJ. Alginate hydrogels as synthetic extracellular matrix materials. Biomaterials. 1999;20(1):45–53. doi:10.1016/s0142-9612(98)00107-0
Trounson A, Thakar RG, Lomax G, Gibbons D. Clinical trials for stem cell therapies. BMC Med. 2011;9:52. doi:10.1186/1741-7015-9-52
Barkholt L, Flory E, Jekerle V, Lucas-Samuel S, Ahnert P, Bisset L, et al. Risk of tumorigenicity in mesenchymal stromal cell-based therapies—bridging scientific observations and regulatory viewpoints. Cytotherapy. 2013;15(7):753–759. doi:10.1016/j.jcyt.2013.03.005
Shi Y, Desponts C, Do JT, Hahm HS, Schöler HR, Ding S. Induction of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule compounds. Cell Stem Cell. 2008;3(5):568–574. doi:10.1016/j.stem.2008.10.004
Morrison SJ, Spradling AC. Stem cells and niches: mechanisms that promote stem cell maintenance throughout life. Cell. 2008;132(4):598–611. doi:10.1016/j.cell.2008.01.038
Deinsberger J, Reisinger D, Weber B. Global trends in clinical trials involving pluripotent stem cells: a systematic multi-database analysis. NPJ Regen Med. 2020;5:15. doi:10.1038/s41536-020-00100-4
Trounson A, Herbert M. Stem cell therapy for diabetes: what is needed to get there? J Intern Med. 2016;280(4):344–353. doi:10.4103/2230-8210.104045
Blau HM, Daley GQ. Stem cells in the treatment of disease. N Engl J Med. 2019;380(18):1748–1760. doi:10.1056/NEJMra1716145
Fernandez-Moure JS. Lost in translation: the gap in scientific advancements and clinical application. Front Bioeng Biotechnol. 2016;4:43. doi:10.3389/fbioe.2016.00043
Robinton DA, Daley GQ. The promise of induced pluripotent stem cells in research and therapy. Nature. 2012;481(7381):295–305. doi:10.1038/nature10761
Zakrzewski W, Dobrzyński M, Szymonowicz M, Rybak Z. Stem cells: past, present, and future. Stem Cell Res Ther. 2019;10(1):68. doi:10.1186/s13287-019-1165-5
Galipeau J, Sensébé L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018;22(6):824–833. doi:10.1016/j.stem.2018.05.004
Toh WS, Brittberg M, Farr J, Foldager CB, Gomoll AH, Hui JHP, Richardson JB, Roberts S, Spector M. Cellular senescence in aging and osteoarthritis. Acta Orthop. 2016;87(sup363):6–14. doi:10.1080/17453674.2016.1235087
Sato T, Clevers H. Growing self-organizing mini-guts from a single intestinal stem cell: mechanism and applications. Science. 2013;340(6137):1190–1194. doi:10.1126/science.1234852
Fisher SA, Doree C, Mathur A, Taggart DP, Martin-Rendon E. Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. Cochrane Database Syst Rev. 2016;12(12):CD007888. doi:10.1002/14651858.CD007888.pub3
Lalu MM, McIntyre L, Pugliese C, Fergusson D, Winston BW, Marshall JC, Granton J, Stewart DJ; Canadian Critical Care Trials Group. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One. 2012;7(10):e47559. doi:10.1371/journal.pone.0047559
Kimbrel EA, Lanza R. Next-generation stem cells—ushering in a new era of cell-based therapies. Nat Rev Drug Discov. 2020;19(7):463-479. doi:10.1038/s41573-020-0064-x
Liu LP, Zheng YW. Predicting differentiation potential of human pluripotent stem cells: possibilities and challenges. World J Stem Cells. 2019 Jul 26;11(7):375–382. doi: https://dx.doi.org/10.4252/wjsc.v11.i7.375
Mimeault M, Hauke R, Batra SK. Stem cells: a revolution in therapeutics—recent advances in stem cell biology and their therapeutic applications in regenerative medicine and cancer therapies. Clin Pharmacol Ther. 2007 Sep;82(3):252–264. doi:10.1038/sj.clpt.6100301
Barry FP, Murphy JM. Mesenchymal stem cells: clinical applications and biological characterization. Int J Biochem Cell Biol. 2004 Apr;36(4):568–584. doi:10.1016/j.biocel.2003.11.001
Lancaster MA, Knoblich JA. Organogenesis in a dish: modeling development and disease using organoid technologies. Science. 2014 Jul 18;345(6194):1247125. doi:10.1126/science.1247125
Li M, Izpisua Belmonte JC. Organoids - Preclinical Models of Human Disease. N Engl J Med. 2019 Feb 7;380(6):569-579. doi:10.1056/NEJMra1806175
Smernoff N. Mesenchymal Stromal Cells and Their Uses in Bio-Regenerative Therapies for Bone and Cartilage: A Review. J Regener Med. 2024 Mar;13(1). doi:10.4236/ojrm.2024.131001
Hussen BM, Taheri M, Yashoo RK, Abdullah GH, Abdullah SR, Kheder RK, Mustafa SA. Revolutionizing medicine: recent developments and future prospects in stem-cell therapy. Int J SSurg. 2024 Dec 1;110(12):8002–8024. doi: 10.1097/JS9.0000000000002109
Fani N, Moradi M, Zavari R, Parvizpour F, Soltani A, Arabpour Z, Jafarian A. Current advances in wound healing and regenerative medicine. Curr Stem Cell Res Ther. 2024;19(3):277–291. doi: 10.2174/1574888X18666230301140659
Morizane R, Lamers MM. Organoids in disease modeling and regenerative medicine. Cell Mol Life Sci. 2025;82(1):169. doi: 10.1007/s00018-025-05692-y
Khodve G, Banerjee S, Kumari M, Ravichandiran V, Banerjee S, Roy S. Exploration of biomaterial and stem cell-based strategies for promoting neuronal regeneration and creating engineered 3D in vitro disease models. J Transl Med. 2025;23:1197. Doi: https://doi.org/10.1186/s12967-025-07266-9
Lamichhane TN, Sokic S, Schardt JS, Raiker RS, Lin JW, Jay SM. Emerging roles for extracellular vesicles in tissue engineering and regenerative medicine. Tissue Eng Part B Rev. 2015;21(1):45–54. doi: 10.1089/ten.teb.2014.0300
Loukelis K, Koutsomarkos N, Mikos AG, Chatzinikolaidou M. Advances in 3D bioprinting for regenerative medicine applications. Regen Biomater. 2024;11:rbae033. doi: 10.1093/rb/rbae033
Zhang D, Yin H, Wu C, Li S, Nabi G, Peng L, Mao X, Jin Z, Li Z, Su X, Huang H. Targeting regulatory T-cells in pancreas during acute pancreatitis: Programmed-death 1 blockage as a potential therapeutic for infectious pancreatic necrosis. Clin Transl Med. 2023;13:1472. doi:https://doi.org/10.1002/ctm2.1472
Chengebroyen N, Seelan A, Thajudeen KY, Alshehri SA, Biswas A, Adur I, Sundararajan V, Sudhakaran SL, Singh H. Harnessing nanotechnology for stem-cell therapies: revolutionizing neurodegenerative disorder treatments – a state-of-the-art update. Front Pharmacol. 2025;16:1630475. doi: 10.3389/fphar.2025.1630475
Patel SA, King CC, Lim PK, Habiba U, Dave M, Porecha R, Rameshwar P. Personalizing stem cell research and therapy: the arduous road ahead or missed opportunity? Curr Pharmacogenomics Person Med. 2010;8(1):1–12. doi:10.2174/1875692111008010025
Chen X, Guo Z, Tong X, Wang X, Liu X, Nagai H, et al. Derivation of embryonic stem cells across avian species. Nat Biotechnol. 2025; doi:https://doi.org/10.1038/s41587-025-02833-3.
Cable J, Fuchs E, Weissman I, Jasper H, Glass D, Rando T, et al. Adult stem cells and regenerative medicine—a symposium report. Ann N Y Acad Sci. 2020;1462(1):27–36. doi:10.1111/nyas.14243.
Knoepfler PS. Deconstructing stem cell tumorigenicity: a roadmap to safe regenerative medicine. Stem Cells. 2009 May;27(5):1050–1056. doi:https://doi.org/10.1002/stem.37.
Wang Z. Assessing tumorigenicity in stem cell-derived therapeutic products: a critical step in safeguarding regenerative medicine. Bioengineering (Basel). 2023 Jul 19;10(7):857. doi:https://doi.org/10.3390/bioengineering10070857.
Tan, F., Li, X., Wang, Z. et al. Clinical applications of stem cell-derived exosomes. Signal Transduct Target Ther 9, 17 (2024). doi https://doi.org/10.1038/s41392-023-01704-0.
Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354(17):1813–26. https://doi.org/10.1056/NEJMra052638.
Trounson A, DeWitt ND. Pluripotent stem cells progressing to the clinic. Nat Rev Mol Cell Biol. 2016;17(3):194–200. https://doi.org/10.1038/nrm.2016.10.
Galipeau J, Sensébé L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018;22(6):824–33. https://doi.org/10.1016/j.stem.2018.05.004.
Driscoll J, Kurtz A. Stem cell therapy: translational challenges. Nat Rev Drug Discov. 2009;8(9):717–24. https://doi.org/10.1038/nrd2978.
Han X, Liao R, Li X, Zhang C, Huo S, Qin L, et al. Mesenchymal stem cells in treating human diseases: molecular mechanisms and clinical studies. Signal Transduct Target Ther. 2025;10:262. doi:https://doi.org/10.1038/s41392-025-02313-9 .
Sekaran, Shamala Devi*; Manikam, Rishya1; Thergerajan, Gaythri2; Prasad, Haymond3; Alagar, Munandy3; Tan, Chung Keat4. The role of personalized precision medicine in enhancing diagnostic accuracy and clinical outcomes. Advances in Biomedical and Health Sciences 4(2):p 52-60, Apr–Jun 2025. | doi: https://doi.org/10.4103/abhs.abhs_105_24.
Ding S. Therapeutic reprogramming toward regenerative medicine. Chem Rev. 2025;125(4):1805–1822. doi:https://doi.org/10.1021/acs.chemrev.4c00332.
Inoue, H., Nagata, N., Kurokawa, H., & Yamanaka, S. (2014). iPS cells: a game changer for future medicine. The EMBO Journal, 33, 409 - 417. https://doi.org/10.1002/embj.201387098.
Mohite, P., Puri, A., Dave, R., Budar, A., Munde, S., Ghosh, S., Alqahtani, T., Shmrany, H., Kumer, A., & Dhara, B. (2024). Unlocking the therapeutic potential: odyssey of induced pluripotent stem cells in precision cell therapies. International Journal of Surgery (London, England), 110, 6432 - 6455. https://doi.org/10.1097/js9.0000000000001892.
Musunuru, K., Sheikh, F., Gupta, R., Houser, S., Maher, K., Milan, D., Terzic, A., & Wu, J. (2018). Induced Pluripotent Stem Cells for Cardiovascular Disease Modeling and Precision Medicine: A Scientific Statement From the American Heart Association.. Circulation: Genomic and Precision Medicine. https://doi.org/10.1161/hcg.0000000000000043.
Aboul-Soud MA, Alzahrani A, Mahmoud A. Induced pluripotent stem cells (iPSCs): roles in regenerative therapies, disease modelling and drug screening. Cells. 2021;10(4):919. https://doi.org/10.3390/cells10040919.
Wang, Z., Zheng, J., Pan, R., & Chen, Y. (2021). Current status and future prospects of patient-derived induced pluripotent stem cells. Human Cell, 34, 1601 - 1616. https://doi.org/10.1007/s13577-021-00592-2.
Madrid, M., Sumen, C., Aivio, S., & Saklayen, N. (2021). Autologous Induced Pluripotent Stem Cell–Based Cell Therapies: Promise, Progress, and Challenges. Current Protocols, 1. https://doi.org/10.1002/cpz1.88.
Rowe, R., & Daley, G. (2019). Induced pluripotent stem cells in disease modelling and drug discovery. Nature Reviews Genetics, 20, 377 - 388. https://doi.org/10.1038/s41576-019-0100-z.
Silva, M., & Haggarty, S. (2019). Human pluripotent stem cell–derived models and drug screening in CNS precision medicine. Annals of the New York Academy of Sciences, 1471. https://doi.org/10.1111/nyas.14012.
Yang Y, et al. A live-cell image-based machine learning strategy for reducing variability in PSC differentiation systems. Cell Discov. 2023;9:43. https://doi.org/10.1038/s41421-023-00543-1.
Frangoul H, et al. CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. N Engl J Med. 2021;384(3):252 60. https://doi.org/10.1056/NEJMoa2031054.
Fatehullah A, Tan SH, Barker N. Organoids as an in vitro model of human development and disease. Nat Cell Biol. 2016;18(3):246–54. https://doi.org/10.1038/ncb3312.
Takebe T, Wells JM. Organoids by design. Science. 2019;364(6444):956–9. https://doi.org/10.1126/science.aaw7567.
Shafiee A, Atala A. Printing technologies for medical applications. Trends Mol Med. 2016;22(3):254 65. https://doi.org/10.1016/j.molmed.2016.01.003.
Dong, Y., Wu, X., Chen, X., Zhou, P., Xu, F., & Liang, W. (2021). Nanotechnology shaping stem cell therapy: Recent advances, application, challenges, and future outlook. Biomedicine & Pharmacotherapy, 137, 111236. https://doi.org/10.1016/j.biopha.2021.111236
Thamarai, P., Karishma, S., Kamalesh, R., Shaji, A., Saravanan, A., Bibi, S., Vickram, A. S., Chopra, H., Saleem, R. A., Alsharif, K. F., Theyab, A., Kamel, M., Alamoudi, M. K., Kumer, A., Chopra, S., & Abdel-Daim, M. M. (2024). Current advancements in nanotechnology for stem cells. International Journal of Surgery, 110(12), 7456–7476. https://doi.org/10.1097/js9.0000000000002082
Bolton, E. M., & Bradley, J. A. (2015). Avoiding Immunological Rejection in Regenerative Medicine. Regenerative Medicine, 10(3), 287–304. https://doi.org/10.2217/rme.15.11
Wood, K. J., Issa, F., & Hester, J. (2016). Understanding Stem Cell Immunogenicity in Therapeutic Applications. Trends in Immunology, 37(1), 5–16. https://doi.org/10.1016/j.it.2015.11.005
Jayaram, P., Danilkowicz, R. M., & Yuan, X. (2025). Ethical and Regulatory Considerations Related to Regenerative Medicine. HSS Journal®: The Musculoskeletal Journal of Hospital for Special Surgery, 21(4), 463–468. https://doi.org/10.1177/15563316251361511
Volarevic, V., Markovic, B. S., Gazdic, M., Volarevic, A., Jovicic, N., Arsenijevic, N., Armstrong, L., Djonov, V., Lako, M., & Stojkovic, M. (2018). Ethical and Safety Issues of Stem Cell-Based Therapy. International Journal of Medical Sciences, 15(1), 36–45. https://doi.org/10.7150/ijms.21666
Hunsberger, J., & Somara, S. (2022). Manufacturing challenges and solutions for regenerative medicine technologies. In Regenerative Nephrology (pp. 487–500). Elsevier. https://doi.org/10.1016/b978-0-12-823318-4.00014-7
Selfa Aspiroz, L., Mennecozzi, M., Batlle, L., Corneo, B., Healy, L., Kotter, M., Kurtz, A., Ludwig, T. E., Mummery, C., Pera, M., Stacey, G. N., Tristan, C. A., & Whelan, M. (2025). Promoting the adoption of best practices and standards to enhance quality and reproducibility of stem cell research. Stem Cell Reports, 20(7), 102531. https://doi.org/10.1016/j.stemcr.2025.102531.
Ahmed SA, Saikia A, Devi SG, Borah JC. AI-assisted cell culture system. Methods Mol Biol. 2025;2952:149–167. doi:10.1007/978-1-0716-4690-8_9.
Kourou K, Exarchos TP, Exarchos KP, Karamouzis MV, Fotiadis DI. Machine learning applications in cancer prognosis and prediction. Comput Struct Biotechnol J. 2015;13:8–17. https://doi.org/10.1016/j.csbj.2014.11.005
Libbrecht MW, Noble WS. Machine learning applications in genetics and genomics. Nat Rev Genet. 2015;16(6):321–32. https://doi.org/10.1038/nrg3920.
Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346(6213):1258096. https://doi.org/10.1126/science.1258096
Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell. 2014;157(6):1262–78. https://doi.org/10.1016/j.cell.2014.05.010
Rossi G, Manfrin A, Lutolf MP. Progress and potential in organoid research. Curr Opin Biotechnol. 2021;66:112–20. https://doi.org/10.1016/j.cotox.2021.08.006
Tang, X.-Y., Wu, S., Wang, D., Chu, C., Hong, Y., Tao, M., Hu, H., Xu, M., Guo, X., & Liu, Y. (2022). Human organoids in basic research and clinical applications. Signal Transduction and Targeted Therapy, 7(1). https://doi.org/10.1038/s41392-022-01024-9
Fetah, K., Tebon, P., Goudie, M. J., Eichenbaum, J., Ren, L., Barros, N., Nasiri, R., Ahadian, S., Ashammakhi, N., Dokmeci, M. R., & Khademhosseini, A. (2019). The emergence of 3D bioprinting in organ-on-chip systems. Progress in Biomedical Engineering, 1(1), 012001. https://doi.org/10.1088/2516-1091/ab23df
Vanaei, S., Parizi, M. S., Vanaei, S., Salemizadehparizi, F., & Vanaei, H. R. (2021). An Overview on Materials and Techniques in 3D Bioprinting Toward Biomedical Application. Engineered Regeneration, 2, 1–18. https://doi.org/10.1016/j.engreg.2020.12.001
Tandon, N., Cimetta, E., Bhumiratana, S., Godier-Furnemont, A., Maidhof, R., & Vunjak-Novakovic, G. (2013). Bioreactors for Tissue Engineering. In Biomaterials Science (pp. 1178–1194). Elsevier. https://doi.org/10.1016/b978-0-08-087780-8.00112-1.
Zhang, H., & Wang, Z. Z. (2008). Mechanisms that mediate stem cell self‐renewal and differentiation. Journal of cellular biochemistry, 103(3), 709-718. https://doi.org/10.1002/jcb.21460
Seita, J., & Weissman, I. L. (2010). Hematopoietic stem cell: self‐renewal versus differentiation. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2(6), 640-653. https://doi.org/10.1002/wsbm.86
Mitalipov, S., & Wolf, D. (2009). Totipotency, pluripotency and nuclear reprogramming. Engineering of stem cells, 185-199. https://doi.org/10.1007/10_2008_45
Jaenisch, R., & Young, R. (2008). Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming. Cell, 132(4), 567-582. https://doi.org/10.1016/j.cell.2008.01.015
Hicks, M. R., & Pyle, A. D. (2023). The emergence of the stem cell niche. Trends in cell biology, 33(2), 112-123. https://doi.org/10.1016/j.tcb.2022.07.003
Scadden, D. T. (2014). Nice neighborhood: emerging concepts of the stem cell niche. Cell, 157(1), 41-50. http://dx.doi.org/10.1016/j.cell.2014.02.013
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright (c) 2026 Shiva Verma, Gopal Jee Tiwari, Saral Shukla, Shraddha Singh, Shanmugapriyan Veeranan (Author)